Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | MGLL | Q99685 | 10/20 | 0.59 |
| ▸ | FAAH | O00519 | 4/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10587456 | 0.83 | MGLL (0.57) | MAPTALDH1A1NPSR1LMNAHPGD | |
| SCHEMBL10587424 | 0.83 | NPSR1 (0.57) | MAPTALDH1A1NPSR1LMNAHPGD | |
| SCHEMBL30645224 | 0.82 | MGLL (0.53) | MAPTALDH1A1NPSR1LMNAHPGD | |
| SCHEMBL15758334 | 0.82 | NPSR1 (0.56) | MAPTALDH1A1NPSR1LMNAHPGD | |
| SCHEMBL30198527 | 0.82 | PKM (0.58) | MAPTALDH1A1NPSR1LMNAHPGD | |
| SCHEMBL15758246 | 0.82 | MGLL (0.53) | MAPTALDH1A1NPSR1LMNAHPGD | |
| SCHEMBL8005849 | 0.82 | PKM (0.58) | MAPTALDH1A1NPSR1LMNAHPGD | |
| SCHEMBL15758697 | 0.82 | MGLL (0.59) | MAPTALDH1A1NPSR1LMNAHPGD | |
| SCHEMBL15758049 | 0.82 | NPSR1 (0.56) | MAPTALDH1A1NPSR1LMNAHPGD | |
| SCHEMBL2938047 | 0.80 | MGLL (0.52) | MAPTALDH1A1NPSR1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250550-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | Ottawa Hospital Research Institute (CA) | 2017-12-06 | — | — | EP | claimed |
| WO-2016119051-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-08-04 | — | — | WO | claimed |
| WO-2016119052-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ONCOLYTIC VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-08-04 | — | — | WO | claimed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220064195-A1 | SYNTHETIC I2 IMIDAZOLINE RECEPTOR LIGANDS FOR PREVENTION OR TREATMENT OF HUMAN BRAIN DISORDERS | UNIVERSITAT DE LES ILLES BALEARS (ES) | 2022-03-03 | — | — | US | disclosed |
| EP-3897838-A1 | <SUP2/>? <SUB2/>?2?SYNTHETIC IIMIDAZOLINE RECEPTOR LIGANDS FOR PREVENTION OR TREATMENT OF HUMAN BRAIN DISORDERS | Universitat de Barcelona (ES) | 2021-10-27 | — | — | EP | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10912761-B2 | Methods and compositions involving RAD51 inhibitors | THE UNIVERSITY OF CHICAGO (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3250550-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | Ottawa Hospital Research Institute (CA) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016119051-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-08-04 | — | — | WO | disclosed |
| CN-1160872-A | Charge controller, toner binder composition and electrophotographic toner | SANYO CHEMICAL IND LTD (JP) | 1997-10-01 | — | — | CN | disclosed |
| EP-0303782-B1 | Resin Composition | SUMITOMO DOW LTD (JP) | 1995-01-11 | — | — | EP | disclosed |
| EP-0267574-B1 | HEAT RESISTANT COPOLYMER COMPOSITION | Sumitomo Dow Limited (JP) | 1993-09-01 | — | — | EP | disclosed |
| US-4877833-A | BLEND OF POLYMERS OF SPECIFIC COMPOSITION | SUMITOMO NAUGATUCK CO., LTD. (JP) | 1989-10-31 | — | — | US | disclosed |
| EP-0303782-A2 | Resin Composition | Sumitomo Dow Limited (JP) | 1989-02-22 | — | — | EP | disclosed |
| EP-0267574-A2 | Heat resistant copolymer composition | Sumitomo Dow Limited (JP) | 1988-05-18 | — | — | EP | disclosed |
| EP-0001997-B1 | ELECTRON BEAM-CURABLE PHOTORESIST LACQUERS | BAYER AG (DE) | 1981-02-11 | — | — | EP | disclosed |
| EP-0001997-A1 | Electron beam-curable photoresist lacquers | BAYER AG (DE) | 1979-05-30 | — | — | EP | disclosed |
| US-4156074-A | Process for the preparation of (thio)hydantoins modified by amide groups | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912761-B2 | Methods and compositions involving RAD51 inhibitors | RAD51, MRE11, RAD50 | MAPT 2482/4885ALDH1A1 3973/4885NPSR1 4816/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | MAPT 1215/4885ALDH1A1 481/4885NPSR1 4214/4885 |
| US-20220064195-A1 | SYNTHETIC I2 IMIDAZOLINE RECEPTOR LIGANDS FOR PREVENTION OR TREATMENT OF HUMAN BRAIN DISORDERS | CHRM1, GPR3, CHRM3 | MAPT 663/4885ALDH1A1 3359/4885NPSR1 76/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | MAPT 1215/4885ALDH1A1 481/4885NPSR1 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.